Literature DB >> 30277314

Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis.

Suat Kucukgoncu1, Urska Kosir1, Elton Zhou1, Erin Sullivan1, Vinod H Srihari1, Cenk Tek1.   

Abstract

AIM: To compare the differences of glucose metabolism outcomes between treatment-naïve, patients with first episode psychosis (FEP) and mood disorders.
METHODS: We conducted a systematic review and meta-analysis of glucose intolerance in treatment-naïve, first episode patients with severe mental illnesses (SMIs).
RESULTS: We identified 31 eligible studies. Compared to healthy controls, FEP group have higher insulin and insulin resistance levels, and both groups have higher glucose tolerance test results. No significant differences were found in glucose metabolism outcomes between FEP and mood disorder groups.
CONCLUSIONS: Our results highlight impaired glucose metabolism at the onset of SMIs, suggesting both patients with psychosis and mood disorders are high-risk groups for diabetes development.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  diabetes; first episode; insulin; mood disorders; psychosis

Mesh:

Substances:

Year:  2018        PMID: 30277314      PMCID: PMC6445792          DOI: 10.1111/eip.12749

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  72 in total

1.  Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up.

Authors:  L Nyboe; C H Vestergaard; M K Moeller; H Lund; P Videbech
Journal:  Schizophr Res       Date:  2015-08-13       Impact factor: 4.939

2.  Carbohydrate metabolism in brain disease. II. Glucose metabolism in Schizophrenic, manic-depressive, and involutional psychoses.

Authors:  D H HENNEMAN; M D ALTSCHULE; R M GONCZ
Journal:  AMA Arch Intern Med       Date:  1954-09

3.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

4.  Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies.

Authors:  Amirhossein Modabbernia; Shervin Taslimi; Elisa Brietzke; Mandana Ashrafi
Journal:  Biol Psychiatry       Date:  2013-02-16       Impact factor: 13.382

Review 5.  Neuroinflammation in schizophrenia especially focused on the role of microglia.

Authors:  Akira Monji; Takahiro A Kato; Yoshito Mizoguchi; Hideki Horikawa; Yoshihiro Seki; Mina Kasai; Yusuke Yamauchi; Shigeto Yamada; Shigenobu Kanba
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-12-13       Impact factor: 5.067

Review 6.  Inflammation and type 2 diabetes.

Authors:  M C Calle; M L Fernandez
Journal:  Diabetes Metab       Date:  2012-01-16       Impact factor: 6.041

Review 7.  The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis.

Authors:  Benjamin Ian Perry; Gemma McIntosh; Scott Weich; Swaran Singh; Karen Rees
Journal:  Lancet Psychiatry       Date:  2016-10-05       Impact factor: 27.083

8.  Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.

Authors:  S Saddichha; N Manjunatha; S Ameen; S Akhtar
Journal:  Acta Psychiatr Scand       Date:  2008-02-26       Impact factor: 6.392

9.  Beyond the brain: disrupted in schizophrenia 1 regulates pancreatic β-cell function via glycogen synthase kinase-3β.

Authors:  Agata Jurczyk; Anetta Nowosielska; Natalia Przewozniak; Ken-Edwin Aryee; Philip DiIorio; David Blodgett; Chaoxing Yang; Martha Campbell-Thompson; Mark Atkinson; Leonard Shultz; Ann Rittenhouse; David Harlan; Dale Greiner; Rita Bortell
Journal:  FASEB J       Date:  2015-11-06       Impact factor: 5.191

10.  Altered systemic cortisol metabolism in bipolar disorder and schizophrenia spectrum disorders.

Authors:  Nils Eiel Steen; Paal Methlie; Steinar Lorentzen; Ingrid Dieset; Monica Aas; Mari Nerhus; Marit Haram; Ingrid Agartz; Ingrid Melle; Jens P Berg; Ole A Andreassen
Journal:  J Psychiatr Res       Date:  2014-02-04       Impact factor: 4.791

View more
  6 in total

1.  Antipsychotic Exposure in Pregnancy and the Risk of Gestational Diabetes: A Systematic Review and Meta-analysis.

Authors:  Suat Kucukgoncu; Sinan Guloksuz; Kubra Celik; Mert Ozan Bahtiyar; Jurjen J Luykx; Bart P F Rutten; Cenk Tek
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

Review 2.  Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder.

Authors:  Cynthia V Calkin
Journal:  Ann Med       Date:  2019-08-27       Impact factor: 4.709

3.  The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients.

Authors:  Albert Danan; Eric C Westman; Laura R Saslow; Georgia Ede
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

4.  Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis.

Authors:  Nuray Çakici; Arjen L Sutterland; Brenda W J H Penninx; Lieuwe de Haan; Nico J M van Beveren
Journal:  Psychol Med       Date:  2021-03-03       Impact factor: 7.723

5.  Scaling Evidence-Based Interventions to Improve the Cardiovascular Health of People With Serious Mental Illness.

Authors:  Christina T Yuan; Emma E McGinty; Arlene Dalcin; Stacy Goldsholl; Faith Dickerson; Kimberly A Gudzune; Gerald J Jerome; David A Thompson; Karly A Murphy; Eva Minahan; Gail L Daumit
Journal:  Front Psychiatry       Date:  2022-02-04       Impact factor: 4.157

Review 6.  Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Authors:  Kah Kheng Goh; Cynthia Yi-An Chen; Tzu-Hua Wu; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.